Life Sciences team advises Nanexa on its SEK 46.1 million exclusivity and evaluation agreement with Novo Nordisk

2 minutes de lecture
11 janvier 2023

Key contact(s):

Our Life Sciences team has advised new Swedish-based client Nanexa on a material transfer and feasibility study agreement with global pharmaceutical company Novo Nordisk A/S. The deal facilitates the evaluation of Nanexa's drug delivery system PharmaShell® with Novo Nordisk products.

Under the evaluation agreement, Nanexa will receive payments of approximately SEK 46.1 million for providing exclusivity and performing work to Novo Nordisk. It has also agreed with its board of directors a directed share issue to Novo Nordisk of 10,000,000 shares, which will raise approximately SEK 17.2 million. In turn, Novo Nordisk will provide Nanexa with its products and Nanexa will develop a long-acting injectable using the PharmaShell® drug delivery system, for evaluation under preclinical studies.

Gowling WLG's head of life sciences in the UK, Patrick Duxbury, led on the deal. He worked closely with Nanexa's chief executive officer David Westberg and director of business development, Otto Skolling.

Patrick Duxbury said: "We are excited to have worked with Nanexa on this latest deal and to further support the development of its drug delivery system PharmaShell®. The in-depth sector expertise of our international team and experience of working with a range of clients in the Nordic region enabled us to focus quickly on our client's priorities and achieve a successful outcome."

Nanexa is a Swedish-headquartered pharmaceutical company focused on developing injectable drug products based on its innovative drug delivery system PharmaShell®. It develops its own products and also has collaboration agreements with several pharmaceutical companies, including AstraZeneca.

Novo Nordisk is global healthcare company, founded in 1923 and headquartered in Denmark. It employs about 53,000 people in 80 countries and markets its products in around 170 countries globally. It was advised on this latest deal by in-house counsel.

CECI NE CONSTITUE PAS UN AVIS JURIDIQUE. L'information qui est présentée dans le site Web sous quelque forme que ce soit est fournie à titre informatif uniquement. Elle ne constitue pas un avis juridique et ne devrait pas être interprétée comme tel. Aucun utilisateur ne devrait prendre ou négliger de prendre des décisions en se fiant uniquement à ces renseignements, ni ignorer les conseils juridiques d'un professionnel ou tarder à consulter un professionnel sur la base de ce qu'il a lu dans ce site Web. Les professionnels de Gowling WLG seront heureux de discuter avec l'utilisateur des différentes options possibles concernant certaines questions juridiques précises.

Sujet(s) similaire(s)   Sciences de la vie